JP Morgan Chase
BBOT

JP Morgan Chase’s BridgeBio Oncology BBOT Stock Holding History

JP Morgan Chase’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-210,125
Closed -$2.24M – 7770
2025
Q2 		$2.24M Buy
210,125
+57,909
+38% +$626K ﹤0.01% 3826
2025
Q1 		$1.72M Buy
+152,216
New +$1.64M ﹤0.01% 3987
2024
Q4 		– Sell
-4
Closed -$42 – 7787
2024
Q3 		$42 Hold
4
– – ﹤0.01% 7149
2024
Q2 		$41 Hold
4
– – ﹤0.01% 7060
2024
Q1 		$41 Buy
+4
New +$41 ﹤0.01% 7076

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

JP Morgan Chase's BBOT Position: Q3 2025 in Review

JP Morgan Chase sold out of BridgeBio Oncology (BBOT) in Q3 2025, closing a stake of 210,125 shares — an estimated $2.24M sold.

JP Morgan Chase first reported a position in BBOT in Q1 2024 and held it in 5 quarters. The position peaked at $2.24M in Q2 2025. 42 funds tracked by Wall St. Rank hold BBOT as of Q3 2025.

  • JP Morgan Chase reported no remaining BridgeBio Oncology position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 210,125 BridgeBio Oncology shares in Q3 2025, an estimated $2.24M.
  • JP Morgan Chase first reported a position in BridgeBio Oncology in Q1 2024 and held it in 5 quarters.
  • JP Morgan Chase's BridgeBio Oncology position peaked at $2.24M in Q2 2025.
  • 42 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.